Yanina Grant-Huerta - 02 Mar 2026 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Role
Chief Accounting Officer
Signature
/s/ John Chao, Attorney-in-Fact for Yanina Grant-Huerta
Issuer symbol
ATRA
Transactions as of
02 Mar 2026
Net transactions value
-$10,691
Form type
4
Filing time
04 Mar 2026, 16:28:21 UTC
Previous filing
19 Nov 2025
Next filing
11 Mar 2026
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Yanina Grant-Huerta filed Form 4 for Atara Biotherapeutics, Inc. (ATRA) on 04 Mar 2026."

Quick Takeaways

  • This page summarizes Yanina Grant-Huerta's Form 4 filing for Atara Biotherapeutics, Inc. (ATRA).
  • 4 reported transactions and 0 derivative rows are listed below.
  • Filing timestamp: 04 Mar 2026, 16:28.

What Changed

  • Previous filing in this sequence was filed on 19 Nov 2025.
  • Current net transaction value: -$10,691.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Grant-Huerta Yanina Chief Accounting Officer C/O ATARA BIOTHERAPEUTICS, INC., 1280 RANCHO CONEJO BOULEVARD, THOUSAND OAKS /s/ John Chao, Attorney-in-Fact for Yanina Grant-Huerta 04 Mar 2026 0002064348

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATRA Common Stock Sale $122 -24 -0.07% $5.08 33,830 02 Mar 2026 Direct F1, F2, F3
transaction ATRA Common Stock Sale $8,145 -1,603 -4.7% $5.08 32,227 02 Mar 2026 Direct F1, F2
transaction ATRA Common Stock Sale $1,916 -377 -1.2% $5.08 31,850 02 Mar 2026 Direct F1, F2
transaction ATRA Common Stock Sale $508 -100 -0.31% $5.08 31,750 02 Mar 2026 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
F3 This amount includes 400 shares purchased under the Issuer's Employee Stock Purchase Plan on November 28, 2025.

Sponsored